Unlock the curative potential of Hematopoietic Stem Cell Transplantation by reducing infections and GvHD

ProTcell, the first ever T cell Progenitors based biotherapy

A new generation of drug transplant product with a cell therapy statuts

Smart Immune is the first clinical-stage biotherapeutics company focused on delivering  the rapid, multipotent curative power of T Cell Progenitors to reboot Immune system to Patient affected by Severe blood cancers or blood inherited diseases .

We are bringing the T Cell Progenitors, a new generation of T cell medicine to Patients in life threatening conditions. Once transplanted to patient, those cells  called ProTcells, differentiate quickly into mature T cell in thymus recipient to reboot immune system and ensure a fast, multipotent protection from all pathogens and cancer cells.

 

Smart Immune patented ProTcell platform technology is applicable to all cell and gene therapies involving T cells, enabling fast improved clinical outcome for patients. With one clinical trial on Severe combined immuno-deficiencies already in clinic,  two clinical trials for Acute Leukemia to be initiated by the end of 2020 and a milli-fluidic automation project enabling bioproduction scalability, Smart Immune aims to make HSCT medicine safer, more effective, and more affordable.

Based in Paris, Smart Immune integrates a collaboration with Necker Enfants Malades Hospital cell and gene therapy teams bringing ground-breaking scientific, clinical and development expertise. With the demonstrated track records of its founders, Marina Cavazzana, MD, PhD, and Isabelle André, PhD, Smart Immune is committed to change Patient prognosis.

Bringing HSCT curative power without adverse events to patients in life threatening conditions

T Cell Progenitors: a new generation of Transplant drug product leading to reduced infections and GvHD risks

A rapid efficiency without adverse events reducing the number of hospitalization days

Automated platform enabling bioproduction Scale up and Scale out